PresentationThank you everyone for joining us this morning. It is nice to see everybody here and online. I'm Elizabeth Anderson. I'm the Health Care Services analyst here at Evercore. I'm very pleased to be joined by Britt Vitalone, a man who needs very little introduction, EVP and CFO of McKesson. Anything you want to kick off with? Otherwise, we'll jump straight into questions.Britt VitaloneExecutive VP & CFO Well, first of all, thank you for having us here. Maybe what I would start with is we're really p ...

McKesson FY Conference Summary Company Overview - **Company**: McKesson Corporation (NYSE: MCK) - **Date of Conference**: December 04, 2025 - **Key Speakers**: Britt Vitalone (EVP and CFO), Elizabeth Anderson (Healthcare Services Analyst at Evercore) Key Points Financial Performance - **Revenue Growth**: 10% revenue growth in the second quarter [2] - **Operating Profit Growth**: Adjusted operating profit growth of 26% [2] - **Earnings Per Share Growth**: Adjusted earnings per share growth of 39% [2] - **Guidance Update**: Raised full-year guidance based on strong performance and cash flow [2] GLP-1 Drugs - **Market Position**: Continued strong growth in GLP-1s, with McKesson providing core distribution and Rx Technology Solutions for affordability and access [5][6] - **Future Outlook**: Positioned well for growth as GLP-1s potentially move to oral solid forms in 2026 [6] Oncology and Multi-Specialty Segment - **Acquisition Contributions**: Increased fiscal 26 AOI contribution guidance from Prism and Florida Cancer Center to $280-$320 million from $220-$270 million [7] - **Oncology Market Opportunity**: Estimated market opportunity of $115 billion, with $80 billion for distribution and GPO services [17] - **Clinical Trials Growth**: 25% year-over-year growth in clinical trial accrual rates [17] Operational Strategy - **Platform Development**: Focus on building platforms in areas with drug investment and innovation, including oncology and vision care [10][11] - **Automation and AI**: Significant investments in automation and AI to modernize operations, with 90% automation in new distribution centers [30][31] Medical Business Separation - **Separation Timeline**: Targeting a tax-free separation and potential IPO in the second half of fiscal 2027 [32][33] - **Focus on Independence**: Separation aimed at allowing the medical business to pursue its own strategies and capital structure [32] 3PL and Distribution Services - **3PL Growth**: Opportunities in established pharma, emerging biopharma, and cell and gene therapy sectors [46][47] - **Cash Pay Prescriptions**: Current cash pay for GLP-1s is small but could grow, presenting potential opportunities for McKesson [48][49] Generic Drugs and Pricing Strategy - **Generics Importance**: Generics remain a crucial part of McKesson's business, with a focus on high service levels and low costs [37][38] - **Pricing Model**: Shifted focus from composite pricing to managing individual generic products for better economic value [40][41] Market Environment and Policy - **Policy Volatility**: Successfully navigating various policy environments, with ongoing discussions with manufacturers regarding service fees [23][24] - **CMMI Demonstration Programs**: Early days for new programs, with McKesson well-positioned regardless of outcomes [26][27] Cash Flow and Investment - **Cash Flow Consistency**: High cash flow conversion historically, expected to continue [55] - **Investment in Rx Technology Solutions**: Increased investment anticipated in the second half of the fiscal year [68] Seasonality and Variability - **Quarterly Variability**: Acknowledgment of potential variations in performance due to seasonality and tax rate changes [64][68] - **Illness Season Impact**: Weaker illness season affecting medical business and some pull-through impacts on pharma business [70][71] Additional Insights - **Strategic Partnerships**: Emphasis on long-term partnerships and shared strategic vision among leadership [62][63] - **Customer-Centric Solutions**: Focus on enhancing customer and provider-centric solutions through technology and service extensions [57][58]

McKesson Corporation (MCK), rooted in 1833, has transformed from a modest drug importer into a formidable global healthcare services force. Based in Irving, Texas, it now commands a vast distribution network spanning pharmaceuticals, medical-surgical supplies, and advanced technology solutions for hospitals, pharmacies, and major health systems. Its scale, logistical strength, and deep integration across the healthcare supply chain position McKesson as an indispensable pillar of modern medical infrastructu ...

Core Insights - McKesson Corporation, based in Irving, Texas, is one of America's oldest businesses with a market capitalization of approximately $105.6 billion, focusing on pharmaceutical distribution, medical supply delivery, and technology solutions [1] Market Performance - Over the past 52 weeks, McKesson's stock has increased by 39.8% and by 51% year-to-date, significantly outperforming the S&P 500 Index, which gained 12.3% and 12.5% in the same periods [2] - The stock has also outperformed the S&P 500 Healthcare Sector SPDR, which saw a 7.5% increase over the past 52 weeks and a 10.9% rise year-to-date [3] Financial Results - For the second quarter of fiscal year 2026, McKesson reported a revenue increase of 10.1% year-over-year, reaching $103.2 billion, aligning with analyst expectations, driven by stronger prescription volumes and broader distribution of oncology and multispecialty products [4] - Earnings per share (EPS) surged 377% annually to $8.92, surpassing expectations, and the management has raised its adjusted EPS outlook for fiscal year 2026 to a range of $38.35 to $38.85 [5] Analyst Outlook - Analysts forecast a 17% EPS growth to $38.66 on a diluted basis for the fiscal year ending in March 2026, with McKesson exceeding analyst expectations for three consecutive quarters [6] - The consensus rating among 16 analysts covering McKesson is "Strong Buy," with 13 "Strong Buy" calls and three "Hold" recommendations [6] - Following the Q2 results, Baird analyst Eric Coldwell raised McKesson's price target to $927 from $873, maintaining an "Outperform" stance, indicating confidence in the company's momentum [7]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - A specific company is highlighted as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for meeting the increasing energy demands of AI technologies [3][7] Investment Landscape - Wall Street is investing hundreds of billions into AI, but there is a looming question regarding the energy supply needed to sustain this growth [2] - AI data centers consume energy equivalent to that of small cities, leading to concerns about power grid strain and rising electricity prices [2] - The company in focus is positioned to benefit from the surge in demand for electricity driven by AI advancements [3][6] Company Profile - The company is described as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend due to tariffs [5][6] - It possesses significant nuclear energy infrastructure assets, making it a crucial player in the U.S. energy strategy [7] - The company is noted for its ability to execute large-scale engineering, procurement, and construction projects across various energy sectors, including oil, gas, and renewables [7] Financial Position - The company is completely debt-free and has a substantial cash reserve, amounting to nearly one-third of its market capitalization [8] - It also holds a significant equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities [9] Market Sentiment - There is a growing interest from hedge funds in this company, which is considered undervalued and off the radar compared to other AI and energy stocks [9][10] - The company is trading at less than 7 times earnings, indicating a potential for significant upside in the context of its critical role in the AI and energy sectors [10] Future Outlook - The ongoing AI infrastructure supercycle, combined with the onshoring boom and increased U.S. LNG exports, positions this company favorably for future growth [14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of energy infrastructure [12][13]

Market Overview - Wall Street experienced a rally as the U.S. Senate made progress toward ending the government shutdown, which was crucial for restoring the flow of official data and improving investor sentiment [1][11] - The S&P 500 rose 1.5% to 6,832.43, the Nasdaq Composite surged 2.3% to 23,527.17, and the Dow Jones Industrial Average advanced 0.8% to 47,368.63 [2] Focus on Financially Resilient Stocks - Companies are often evaluated based on sales and earnings, but these metrics alone may not provide a complete picture of financial health [3] - A critical analysis of a company's financial background, particularly the Interest Coverage Ratio, is essential for informed investment decisions [4][7] - The Interest Coverage Ratio indicates a company's ability to pay interest on its debt, with a higher ratio suggesting a stronger financial position [5][8] Interest Coverage Ratio Insights - The Interest Coverage Ratio is calculated as Earnings before Interest & Taxes (EBIT) divided by Interest Expense [5] - A ratio below 1.0 indicates potential default risk, while a higher ratio suggests the company can withstand financial hardships [9] - Companies with strong interest coverage ratios highlighted include Life Time Group Holdings, Inc. (LTH), Cardinal Health, Inc. (CAH), McKesson Corporation (MCK), and Flowserve Corporation (FLS) [11] Company Performance Highlights - Life Time Group has a Zacks Rank of 2, with projected sales growth of 13.7% and EPS growth of 51.6% for the current financial year [16] - Cardinal Health also holds a Zacks Rank of 2, with sales and EPS growth estimates of 15.2% and 18.8%, respectively, and a significant stock increase of 66.3% over the past year [17] - McKesson Corporation, with a Zacks Rank of 2, anticipates sales and EPS growth of 13.8% and 15.6%, but has seen a stock decline of 16.1% in the past year [18] - Flowserve, also ranked 2, projects sales growth of 4.9% and EPS growth of 31.2%, with a stock increase of 15.3% over the past year [19]

Core Insights - The North American Pharmaceutical business has shown stronger-than-expected margins when separated from the Specialty business, indicating underlying improvements in the sector [1] Group 1: Business Performance - The North American Pharma margins, excluding Oncology and Specialty, were stronger than anticipated, suggesting positive changes in the business dynamics [1] - The integration of Canada into the North American Pharma segment may have contributed to the improved performance [1] Group 2: Market Dynamics - The ongoing tracking of generic pricing and mix indicates that these factors have remained stable, yet other elements within the business are driving improvements [1]

Summary of McKesson's 2025 Conference Call Company Overview - **Company**: McKesson Corporation (NYSE: MCK) - **Event**: UBS Healthcare Conference - **Date**: November 10, 2025 Key Points Industry Insights - **North American Pharmaceutical Business**: McKesson has resegmented its business to provide clarity on strategies, separating specialty oncology from the North American Pharmaceutical segment, which includes the US Pharma and Canadian distribution businesses [3][5][6] - **Market Trends**: The company has observed consistent growth in utilization, driven by demographic trends and innovations in drug development and distribution [7][9] - **Specialty Drugs**: There is a notable shift towards specialty drugs, which are becoming a larger part of the business mix, contributing to improved margins [9][10] Financial Performance - **Operating Expense Leverage**: Over the past five years, McKesson has improved its operating expense leverage by over 1,000 basis points, attributed to investments in automation and technology [17][18] - **Revenue Growth**: The adjusted EPS guidance for the year is between $38.35 and $38.85, representing a growth of 16%-18%, or 18%-20% when excluding prior year gains [63] Strategic Initiatives - **Automation and AI**: McKesson is investing in automation and AI to enhance operational efficiency, with a new distribution center in Ohio being 90% automated [16][18] - **Oncology and Specialty Services**: The company is focused on expanding its oncology services and exploring opportunities in other specialties, particularly in high drug spend areas like retina and ophthalmology [35][44] Pricing and Market Dynamics - **Generic Pricing**: The pricing environment for generics has been stable, with month-to-month variations not significantly impacting long-term strategies [21][22] - **Impact of Legislation**: McKesson does not foresee direct impacts from recent legislative changes regarding drug pricing, as they continue to negotiate fair value for their services [24][25] Future Opportunities - **Clinical Trials and Research**: McKesson sees potential in expanding clinical trial access and management through its Sarah Cannon Research Institute joint venture, which could enhance its oncology platform [33][34] - **New Therapeutic Areas**: The company is exploring opportunities in other therapeutic areas with high innovation and drug spend, beyond oncology and ophthalmology [44][45] Operational Considerations - **Working Capital Management**: McKesson is focused on efficient working capital management, ensuring that fixed fees for services remain unaffected by fluctuations in drug prices [28][29] - **GPO and MSO Dynamics**: The Group Purchasing Organization (GPO) services a wide range of providers, and the company is looking to grow beyond drug distribution into additional service offerings [49] Conclusion - McKesson is strategically positioned to leverage its capabilities in the North American pharmaceutical market, focusing on specialty drugs, operational efficiency through automation, and expanding its oncology services while navigating the evolving regulatory landscape. The company anticipates continued growth and opportunities in high drug spend areas, supported by its investments in technology and clinical services.

Core Insights - McKesson Corporation reported strong adjusted earnings per share (EPS) of $9.86 for Q2 fiscal 2026, exceeding estimates by 10.5% and showing a year-over-year increase of 39.5% driven by operational growth and acquisitions [1] - Total revenues reached $103.15 billion, a 10.1% increase year-over-year, but fell short of estimates by 1.4% [3] - The company raised its fiscal 2026 EPS guidance to $38.35-$38.85, reflecting confidence in demand and growth across its segments [15] Revenue and Earnings Performance - Adjusted EPS of $9.86 beat the Zacks Consensus Estimate of $8.92, with GAAP EPS reported at $8.92 compared to $1.87 in the prior year [1][2] - Revenues of $103.15 billion increased by 10.1% year-over-year, driven by higher prescription volumes and growth in oncology and specialty products [3] - The North American Pharmaceutical segment generated $86.48 billion in revenue, up 8.1% year-over-year, attributed to increased prescription volumes [7] Segment Analysis - The Oncology & Multispecialty segment reported revenues of $12.04 billion, a significant increase of 31.5% year-over-year, with adjusted operating profit rising 71.1% to $397 million [9] - The Prescription Technology Solutions segment saw revenues of $1.38 billion, up 8.8% year-over-year, with adjusted operating profit increasing 19.7% to $261 million [10] - The Medical-Surgical Solutions segment's revenues remained flat at $2.95 billion, with adjusted operating profit up 2.5% to $249 million [11] Financial Metrics - Adjusted gross profit was $3.53 billion, an increase of 8.9% year-over-year, representing 3.4% of net revenues [12] - Adjusted operating income rose 24.9% to $1.57 billion, with an operating margin of 1.5%, expanding nearly 18 basis points year-over-year [13] - Cash and cash equivalents increased to $4 billion from $2.42 billion in the previous quarter, with cumulative net cash from operating activities at $1.5 billion [14] Strategic Initiatives - McKesson is modernizing its distribution through automation and compliance with DSCSA, enhancing its operational capabilities [18] - The company is advancing its portfolio transformation, including plans to spin off the Medical-Surgical Solutions business by the second half of calendar 2027 [18] - New capabilities in high-complexity therapies and rising demand for automated access tools are expected to drive future growth [17]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have ad-blockers enabled [1]